By disrupting such circuitries, we set up a new pharmacological strategy that induces chemo-immuno-sensitization in NSCLC with low levels of TFEB, characterized by the worst response to chemotherapy and immuno-killing. The gene discussed is TFEB; the disease is non-small cell lung carcinoma.